Compare KMT & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | ABSI |
|---|---|---|
| Founded | 1938 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 1994 | 2021 |
| Metric | KMT | ABSI |
|---|---|---|
| Price | $31.86 | $8.92 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $32.43 | $14.40 |
| AVG Volume (30 Days) | 1.2M | ★ 3.8M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ 268.33 | 10.64 |
| EPS | ★ 4.42 | N/A |
| Revenue | ★ $2,356,698,000.00 | $4,534,000.00 |
| Revenue This Year | $43.37 | $39.03 |
| Revenue Next Year | $3.64 | $310.91 |
| P/E Ratio | $7.27 | ★ N/A |
| Revenue Growth | ★ 19.82 | N/A |
| 52 Week Low | $20.38 | $2.24 |
| 52 Week High | $43.81 | $12.06 |
| Indicator | KMT | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 45.29 |
| Support Level | $28.73 | $8.17 |
| Resistance Level | $35.50 | $10.03 |
| Average True Range (ATR) | 1.00 | 0.87 |
| MACD | 0.30 | -0.07 |
| Stochastic Oscillator | 56.98 | 4.06 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.